Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Authors

Brad A. Racette, Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu
Mikula Stambuk
Joel S. Perlmutter

Document Type

Article

Abstract

We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.

Medical Subject Headings

Blepharospasm (drug therapy); Blinking (drug effects); Botulinum Toxins, Type A (pharmacology, therapeutic use); Female; Humans; Middle Aged; Treatment Outcome

Publication Date

9-1-2002

Publication Title

Movement disorders : official journal of the Movement Disorder Society

ISSN

0885-3185

Volume

17

Issue

5

First Page

1098

Last Page

100

PubMed ID

12360571

Digital Object Identifier (DOI)

10.1002/mds.10209

Recommended Citation

Racette, Brad A.; Stambuk, Mikula; and Perlmutter, Joel S., "Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)" (2002). Neurology. 1177.
https://scholar.barrowneuro.org/neurology/1177